共 197 条
[1]
January CT(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons Circulation 140 e125-e151
[2]
Wann LS(2013)Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2093-2104
[3]
Calkins H(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 981-992
[4]
Chen LY(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 883-891
[5]
Cigarroa JE(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139-1151
[6]
Cleveland JJ(2019)Efficacy and safety of the use of non-vitamin K antagonist Oral anticoagulants in patients with ischemic heart disease: a meta-analysis of phase III randomized trials Am J Cardiovasc Drugs 19 37-47
[7]
Ellinor PT(2016)Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48 Eur J Heart Fail 18 1153-1161
[8]
Ezekowitz MD(2016)Comparison of Dabigatran and warfarin in patients with atrial fibrillation and Valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy) Circulation 134 589-598
[9]
Field ME(2019)Non-vitamin K antagonist Oral anticoagulants versus warfarin in patients with Cancer and atrial fibrillation: a systematic review and meta-analysis J Am Heart Assoc 8 e12540-60
[10]
Furie KL(2020)Efficacy and safety of direct Oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis Am J Cardiovasc Drugs 20 51-816